Darryl Sleep on Engasertib: This is a Significant Step Forward for Patients Dealing with HHT
Darryl Sleep, Former Head Global Public Health at Amgen, BioPharma Executive, reposted from Vaderis Therapeutics AG on LinkedIn:
”This is a significant step forward for patients dealing with Hereditary Hemorrhagic Telangiectasia (HHT), the second most common inherited bleeding disorder.
This is the result of collaboration and partnership across the entire HHT community of researchers, academics, patient advocacy, patients and caregivers with a focused, targeted approach to address a major medical need for patients who do not have an approved therapeutic.
Vaderis and our partners are moving forward with urgency and a commitment to patients to initiate the Phase 3 HEROIC study in 2026.
Patients living with HHT can’t wait for effective therapies to improve their lives.”
Quoting Vaderis Therapeutics AG‘s post:
”Moving Forward Together for the HHT Community
We’re honored to share that The New England Journal of Medicine has published results from our clinical study of engasertib (VAD044) in Hereditary Hemorrhagic Telangiectasia (HHT).
This milestone reflects the dedication of patients, families, and advocacy partners who made this research possible.
While more work lies ahead, these published findings strengthen our commitment to developing a potential new treatment option for a community that has long gone without approved therapies.
As we prepare for the Phase 3 HEROIC study in 2026, we remain focused on bringing hope and meaningful progress to people living with HHT.
Read the full press release.”
Stay updated with Hemostasis Today.
-
Mar 7, 2026, 15:05Isabelle Mahé: Cancer Site, Bleeding Risk, and Reduced-Dose Apixaban in Cancer-Associated Thrombosis
-
Mar 7, 2026, 14:58Nicole Juffermans: Comparing the Effect of Plasma Versus Clear Fluids on Intravascular Volume
-
Mar 7, 2026, 14:55Alfadil Haroon: New Genetic Insights into Bone Marrow Failure Syndromes
-
Mar 7, 2026, 14:48Shaine Morris: Save the Date for the Texas Children’s Hospital Second Pediatric Aortopathy Symposium
-
Mar 7, 2026, 14:46Ahmad Hazri Mohamed Aris: Strengthening Bleeding Disorders Care Through WFH PACT 2026–2030
-
Mar 7, 2026, 14:42Megan Adediran: When Should Heavy Bleeding Stop Being Called Normal?
-
Mar 7, 2026, 14:41Heghine Khachatryan: Best-Practice Recommendations for Implementing Shared Decision-Making in Hemophilia Care
-
Mar 7, 2026, 14:37Julie Kennedy Lesch: Driving Progress for People Living with Sickle Cell Disease
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology